Novel immunotherapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 6, 2005
app pub date -
Apr 2, 2004
filing date -
Apr 2, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes .alpha.6.beta.1 integrin receptors and/or .alpha.6.beta.4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 .alpha.3 chain that has been shown to bind .alpha.6.beta.1 integrin receptors and .alpha.6.beta.4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 .alpha.3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully